Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
City of Hope Medical Center
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
University of Nebraska
The Lymphoma Academic Research Organisation
Yale University
Celgene
National Cancer Institute (NCI)